Medigen Vaccine Biologics (6547) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medigen Vaccine Biologics (6547) has a cash flow conversion efficiency ratio of 0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$101.08 Million ≈ $3.18 Million USD) by net assets (NT$3.48 Billion ≈ $109.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medigen Vaccine Biologics - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Medigen Vaccine Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 6547 current and long-term liabilities for a breakdown of total debt and financial obligations.
Medigen Vaccine Biologics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medigen Vaccine Biologics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hwail Pharmaceutical Co.Ltd
KQ:061250
|
0.033x |
|
Chongqing Mas Sci&Tech
SHE:300275
|
0.015x |
|
Donegal Group A Inc
NASDAQ:DGICA
|
0.016x |
|
HCR Co Ltd
SHG:688500
|
0.001x |
|
Lumibird SA
PA:LBIRD
|
0.038x |
|
Trakcja PRKiI S.A.
WAR:TRK
|
0.206x |
|
Tangel Publishing
SHE:300148
|
-0.009x |
|
OPTHEA LTD (SP.ADR/8)
F:UKJ2
|
N/A |
Annual Cash Flow Conversion Efficiency for Medigen Vaccine Biologics (2012–2025)
The table below shows the annual cash flow conversion efficiency of Medigen Vaccine Biologics from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Medigen Vaccine Biologics.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$3.48 Billion ≈ $109.62 Million |
NT$-49.09 Million ≈ $-1.55 Million |
-0.014x | -233.28% |
| 2024-12-31 | NT$3.85 Billion ≈ $121.30 Million |
NT$40.75 Million ≈ $1.28 Million |
0.011x | +108.52% |
| 2023-12-31 | NT$3.85 Billion ≈ $121.19 Million |
NT$-477.75 Million ≈ $-15.05 Million |
-0.124x | +43.27% |
| 2022-12-31 | NT$5.03 Billion ≈ $158.44 Million |
NT$-1.10 Billion ≈ $-34.69 Million |
-0.219x | -276.53% |
| 2021-12-31 | NT$4.68 Billion ≈ $147.32 Million |
NT$579.89 Million ≈ $18.27 Million |
0.124x | +166.03% |
| 2020-12-31 | NT$3.14 Billion ≈ $98.97 Million |
NT$-589.97 Million ≈ $-18.59 Million |
-0.188x | +44.52% |
| 2019-12-31 | NT$1.37 Billion ≈ $43.06 Million |
NT$-462.65 Million ≈ $-14.58 Million |
-0.338x | -53.14% |
| 2018-12-31 | NT$1.61 Billion ≈ $50.79 Million |
NT$-356.33 Million ≈ $-11.23 Million |
-0.221x | -54.92% |
| 2017-12-31 | NT$1.52 Billion ≈ $47.92 Million |
NT$-217.03 Million ≈ $-6.84 Million |
-0.143x | -28.34% |
| 2016-12-31 | NT$1.47 Billion ≈ $46.30 Million |
NT$-163.37 Million ≈ $-5.15 Million |
-0.111x | -169.10% |
| 2015-12-31 | NT$1.34 Billion ≈ $42.35 Million |
NT$216.26 Million ≈ $6.81 Million |
0.161x | +133.76% |
| 2014-12-31 | NT$1.08 Billion ≈ $33.99 Million |
NT$-513.98 Million ≈ $-16.19 Million |
-0.476x | -201.54% |
| 2013-12-31 | NT$457.94 Million ≈ $14.43 Million |
NT$-72.36 Million ≈ $-2.28 Million |
-0.158x | -269.62% |
| 2012-12-31 | NT$128.00 Million ≈ $4.03 Million |
NT$-5.47 Million ≈ $-172.40K |
-0.043x | -- |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more